Antiretroviral restriction factors in mice

Virus Research

Volumn 193, Issue , 2014, Pages 130-134

  Nair, Smita ^a,b   Rein, Alan ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

APOBEC3; Fv1 restriction; Murine leukemia virus; Retrovirus; Tetherin

Indexed keywords

CELL PROTEIN; PROTEIN APOBEC3; PROTEIN FV1; PROTEIN TETHERIN; UNCLASSIFIED DRUG; APOBEC3 PROTEIN, MOUSE; BST2 PROTEIN, MOUSE; CYTIDINE DEAMINASE; FV1 PROTEIN, MOUSE; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; PROTEIN;

ALLELE; ARTICLE; CARBOXY TERMINAL SEQUENCE; EQUINE INFECTIOUS ANEMIA VIRUS; FRIEND LEUKEMIA VIRUS; GENE REPRESSION; HETEROKARYON; HUMAN IMMUNODEFICIENCY VIRUS 1; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; RETROPOSON; VIRUS ENTRY; VIRUS GENOME; VIRUS PARTICLE; VIRUS REPLICATION; ZINC FINGER MOTIF; ANIMAL; GENETICS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; MOUSE; PHYSIOLOGY; RETROVIRIDAE; RETROVIRUS INFECTION; VIROLOGY;

MURINE LEUKEMIA VIRUS; MUS;

ANIMALS; ANTIGENS, CD; CYTIDINE DEAMINASE; HOST-PATHOGEN INTERACTIONS; IMMUNITY, INNATE; MEMBRANE GLYCOPROTEINS; MICE; PROTEINS; RETROVIRIDAE; RETROVIRIDAE INFECTIONS;

EID: 84914162928     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2014.07.002     Document Type: Article

References (80)

1. Andrew A.J., Miyagi E., Kao S., Strebel K. The formation of cysteine-linked dimers of BST-2/tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu. Retrovirology 2009, 6:80.
2. Barrett B.S., Smith D.S., Li S.X., Guo K., Hasenkrug K.J., Santiago M.L. A single nucleotide polymorphism in tetherin promotes retrovirus restriction in vivo. PLoS Pathog. 2012, 8(3):e1002596.
3. Bassin R.H., Gerwin B.I., Duran-Troise G., Gisselbrecht S., Rein A. Murine sarcoma virus pseudotypes acquire a determinant specifying N or B tropism from leukaemia virus during rescue. Nature 1975, 256(5514):223-225.
4. Bassin R.H., Gerwin B.I., Levin J.G., Duran-Troise G., Benjers B.M., Rein A. Macromolecular requirements for abrogation of Fv-1 restriction by murine leukemia viruses. J. Virol. 1980, 35(2):287-297.
5. Best S., Le Tissier P., Towers G., Stoye J.P. Positional cloning of the mouse retrovirus restriction gene Fv1. Nature 1996, 382(6594):826-829. (see comments).
6. Bishop K.N., Bock M., Towers G., Stoye J.P. Identification of the regions of Fv1 necessary for murine leukemia virus restriction. J. Virol. 2001, 75(11):5182-5188.
7. Bishop K.N., Mortuza G.B., Howell S., Yap M.W., Stoye J.P., Taylor I.A. Characterization of an amino-terminal dimerization domain from retroviral restriction factor Fv1. J. Virol. 2006, 80(16):8225-8235.
8. Browne E.P., Littman D.R. Species-specific restriction of apobec3-mediated hypermutation. J. Virol. 2008, 82(3):1305-1313.
9. Cao W., Bover L., Cho M., Wen X., Hanabuchi S., Bao M., Rosen D.B., Wang Y.H., Shaw J.L., Du Q., Li C., Arai N., Yao Z., Lanier L.L., Liu Y.J. Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction. J. Exp. Med. 2009, 206(7):1603-1614.
10. Carmi S., Church G.M., Levanon E.Y. Large-scale DNA editing of retrotransposons accelerates mammalian genome evolution. Nat. Commun. 2011, 2:519.
11. Chaurasiya K.R., McCauley M.J., Wang W., Qualley D.F., Wu T., Kitamura S., Geertsema H., Chan D.S., Hertz A., Iwatani Y., Levin J.G., Musier-Forsyth K., Rouzina I., Williams M.C. Oligomerization transforms human APOBEC3G from an efficient enzyme to a slowly dissociating nucleic acid-binding protein. Nat. Chem. 2014, 6(1):28-33.
12. Corbin A., Prats A.C., Darlix J.L., Sitbon M. A nonstructural gag-encoded glycoprotein precursor is necessary for efficient spreading and pathogenesis of murine leukemia viruses. J. Virol. 1994, 68(6):3857-3867.
13. Duran-Troise G., Bassin R.H., Rein A., Gerwin B.I. Loss of Fv-1 restriction in Balb/3T3 cells following infection with a single N tropic murine leukemia virus particle. Cell 1977, 10(3):479-488.
14. Duran-Troise G., Bassin R.H., Wallace B.F., Rein A. Balb/3T3 cells chronically infected with N-tropic murine leukemia virus continue to express Fv-1b restriction. Virology 1981, 112(2):795-799.
15. Elis E., Ehrlich M., Prizan-Ravid A., Laham-Karam N., Bacharach E. p12 tethers the murine leukemia virus pre-integration complex to mitotic chromosomes. PLoS Pathog. 2012, 8(12):e1003103.
16. Esnault C., Millet J., Schwartz O., Heidmann T. Dual inhibitory effects of APOBEC family proteins on retrotransposition of mammalian endogenous retroviruses. Nucleic Acids Res. 2006, 34(5):1522-1531.
17. Fan H., Chute H., Chao E., Feuerman M. Construction and characterization of Moloney murine leukemia virus mutants unable to synthesize glycosylated gag polyprotein. Proc. Natl. Acad. Sci. U.S.A. 1983, 80(19):5965-5969.
18. Geraghty R.J., Talbot K.J., Callahan M., Harper W., Panganiban A.T. Cell type-dependence for Vpu function. J. Med. Primatol. 1994, 23(2-3):146-150.
19. Goffinet C., Schmidt S., Kern C., Oberbremer L., Keppler O.T. Endogenous CD317/Tetherin limits replication of HIV-1 and murine leukemia virus in rodent cells and is resistant to antagonists from primate viruses. J. Virol. 2010, 84(21):11374-11384.
20. Gottlinger H.G., Dorfman T., Cohen E.A., Haseltine W.A. Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses. Proc. Natl. Acad. Sci. U.S.A. 1993, 90(15):7381-7385.
21. Hakata Y., Landau N.R. Reversed functional organization of mouse and human APOBEC3 cytidine deaminase domains. J. Biol. Chem. 2006, 281(48):36624-36631.
22. Hilditch L., Matadeen R., Goldstone D.C., Rosenthal P.B., Taylor I.A., Stoye J.P. Ordered assembly of murine leukemia virus capsid protein on lipid nanotubes directs specific binding by the restriction factor, Fv1. Proc. Natl. Acad. Sci. U.S.A. 2011, 108(14):5771-5776.
23. Hopkins N., Schindler J., Hynes R. Six-NB-tropic murine leukemia viruses derived from a B-tropic virus of BALB/c have altered p30. J. Virol. 1977, 21(1):309-318.
24. Jarmuz A., Chester A., Bayliss J., Gisbourne J., Dunham I., Scott J., Navaratnam N. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 2002, 79(3):285-296.
25. Jern P., Stoye J.P., Coffin J.M. Role of APOBEC3 in genetic diversity among endogenous murine leukemia viruses. PLoS Genet. 2007, 3(10):2014-2022.
26. Jolicoeur P., Baltimore D. Effect of Fv-1 gene product on proviral DNA formation and integration in cells infected with murine leukemia viruses. Proc. Natl. Acad. Sci. U.S.A. 1976, 73(7):2236-2240.
27. Jolicoeur P., Rassart E. Effect of Fv-1 gene product on synthesis of linear and supercoiled viral DNA in cells infected with murine leukemia virus. J. Virol. 1980, 33(1):183-195.
28. Jones P.H., Mehta H.V., Maric M., Roller R.J., Okeoma C.M. Bone marrow stromal cell antigen 2 (BST-2) restricts mouse mammary tumor virus (MMTV) replication in vivo. Retrovirology 2012, 9:10.
29. Jung Y.T., Kozak C.A. A single amino acid change in the murine leukemia virus capsid gene responsible for the Fv1(nr) phenotype. J. Virol. 2000, 74(11):5385-5387.
30. Kolokithas A., Rosenke K., Malik F., Hendrick D., Swanson L., Santiago M.L., Portis J.L., Hasenkrug K.J., Evans L.H. The glycosylated Gag protein of a murine leukemia virus inhibits the antiretroviral function of APOBEC3. J. Virol. 2010, 84(20):10933-10936.
31. Kozak C.A., Chakraborti A. Single amino acid changes in the murine leukemia virus capsid protein gene define the target of Fv1 resistance. Virology 1996, 225(2):300-305.
32. Langlois M.A., Kemmerich K., Rada C., Neuberger M.S. The Akv murine leukemia virus is restricted and hypermutated by mouse Apobec3. J. Virol. 2009, 83:11550-11559.
33. Liberatore R.A., Bieniasz P.D. Tetherin is a key effector of the antiretroviral activity of type I interferon in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 2011, 108(44):18097-18101.
34. Lilly F. Fv-2: identification and location of a second gene governing the spleen focus response to Friend leukemia virus in mice. J. Natl. Cancer Inst. 1970, 45(1):163-169.
35. Low A., Okeoma C.M., Lovsin N., de las Heras M., Taylor T.H., Peterlin B.M., Ross S.R., Fan H. Enhanced replication and pathogenesis of Moloney murine leukemia virus in mice defective in the murine APOBEC3 gene. Virology 2009, 385(2):455-463.
36. MacMillan A.L., Kohli R.M., Ross S.R. APOBEC3 inhibition of mouse mammary tumor virus infection: the role of cytidine deamination versus inhibition of reverse transcription. J. Virol. 2013, 87(9):4808-4817.
37. Mariani R., Chen D., Schrofelbauer B., Navarro F., Konig R., Bollman B., Munk C., Nymark-McMahon H., Landau N.R. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 2003, 114(1):21-31.
38. Meyerson N.R., Sawyer S.L. Two-stepping through time: mammals and viruses. Trends Microbiol. 2011, 19(6):286-294.
39. Nair S., Sanchez-Martinez S., Ji X., Rein A. Biochemical and biological studies of mouse APOBEC3. J. Virol. 2014, 88(7):3850-3860.
40. Neil S.J., Sandrin V., Sundquist W.I., Bieniasz P.D. An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. Cell Host Microbe 2007, 2(3):193-203.
41. Neil S.J., Zang T., Bieniasz P.D. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008, 451(7177):425-430.
42. Nitta T., Lee S., Ha D., Arias M., Kozak C.A., Fan H. Moloney murine leukemia virus glyco-gag facilitates xenotropic murine leukemia virus-related virus replication through human APOBEC3-independent mechanisms. Retrovirology 2012, 9:58.
43. Okeoma C.M., Huegel A.L., Lingappa J., Feldman M.D., Ross S.R. APOBEC3 proteins expressed in mammary epithelial cells are packaged into retroviruses and can restrict transmission of milk-borne virions. Cell Host Microbe 2010, 8(6):534-543.
44. Okeoma C.M., Lovsin N., Peterlin B.M., Ross S.R. APOBEC3 inhibits mouse mammary tumour virus replication in vivo. Nature 2007, 445(7130):927-930.
45. Okeoma C.M., Petersen J., Ross S.R. Expression of murine APOBEC3 alleles in different mouse strains and their effect on mouse mammary tumor virus infection. J. Virol. 2009, 83(7):3029-3038.
46. Perez-Caballero D., Zang T., Ebrahimi A., McNatt M.W., Gregory D.A., Johnson M.C., Bieniasz P.D. Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 2009, 139(3):499-511.
47. Pincus T., Hartley J.W., Rowe W.P. A major genetic locus affecting resistance to infection with murine leukemia viruses. I. Tissue culture studies of naturally occurring viruses. J. Exp. Med. 1971, 133(6):1219-1233.
48. Qi C.F., Bonhomme F., Buckler-White A., Buckler C., Orth A., Lander M.R., Chattopadhyay S.K., Morse H.C. Molecular phylogeny of Fv1. Mamm. Genome 1998, 9(12):1049-1055.
49. Rein A., Kashmiri S.V., Bassin R.H., Gerwin B.L., Duran-Troise G. Phenotypic mixing between N- and B-tropic murine leukemia viruses: infectious particles with dual sensitivity to Fv-1 restriction. Cell 1976, 7(3):373-379.
50. Ribet D., Dewannieux M., Heidmann T. An active murine transposon family pair: retrotransposition of master MusD copies and ETn trans-mobilization. Genome Res. 2004, 14(11):2261-2267.
51. Rommelaere J., Donis-Keller H., Hopkins N. RNA sequencing provides evidence for allelism of determinants of the N-, B- or NB-tropism of murine leukemia viruses. Cell 1979, 16(1):43-50.
52. Rowe W.P., Humphrey J.B., Lilly F. A major genetic locus affecting resistance to infection with murine leukemia viruses. 3. Assignment of the Fv-1 locus to linkage group 8 of the mouse. J. Exp. Med. 1973, 137(3):850-853.
53. Rulli S.J., Mirro J., Hill S.A., Lloyd P., Gorelick R.J., Coffin J.M., Derse D., Rein A. Interactions of murine APOBEC3 and human APOBEC3G with murine leukemia viruses. J. Virol. 2008, 82(13):6566-6575.
54. Sakai H., Tokunaga K., Kawamura M., Adachi A. Function of human immunodeficiency virus type 1 Vpu protein in various cell types. J. Gen. Virol. 1995, 76(Pt 11):2717-2722.
55. Sanchez-Martinez S., Aloia A.L., Harvin D., Mirro J., Gorelick R.J., Jern P., Coffin J.M., Rein A. Studies on the restriction of murine leukemia viruses by mouse APOBEC3. PLoS One 2012, 7(5):e38190.
56. Santiago M.L., Montano M., Benitez R., Messer R.J., Yonemoto W., Chesebro B., Hasenkrug K.J., Greene W.C. Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection. Science 2008, 321(5894):1343-1346.
57. Sanville B., Dolan M.A., Wollenberg K., Yan Y., Martin C., Yeung M.L., Strebel K., Buckler-White A., Kozak C.A. Adaptive evolution of Mus Apobec3 includes retroviral insertion and positive selection at two clusters of residues flanking the substrate groove. PLoS Pathog. 2010, 6(7):e1000974.
58. Sanz-Ramos M., Stoye J.P. Capsid-binding retrovirus restriction factors: discovery, restriction specificity and implications for the development of novel therapeutics. J. Gen. Virol. 2013, 94(Pt 12):2587-2598.
59. Schindler J., Hynes R., Hopkins N. Evidence for recombination between N- and B-tropic murine leukemia viruses: analysis of three virion proteins by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. J. Virol. 1977, 23(3):700.
60. Schneider W.M., Brzezinski J.D., Aiyer S., Malani N., Gyuricza M., Bushman F.D., Roth M.J. Viral DNA Tethering Domains Complement Replication-Defective Mutations in the p12 Protein of MuLV Gag 2013.
61. Schwartzberg P., Colicelli J., Goff S.P. Deletion mutants of Moloney murine leukemia virus which lack glycosylated gag protein are replication competent. J. Virol. 1983, 46(2):538-546.
62. Sheehy A.M., Gaddis N.C., Choi J.D., Malim M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002, 418(6898):646-650.
63. Stavrou S., Nitta T., Kotla S., Ha D., Nagashima K., Rein A.R., Fan H., Ross S.R. Murine leukemia virus glycosylated Gag blocks apolipoprotein B editing complex 3 and cytosolic sensor access to the reverse transcription complex. Proc. Natl. Acad. Sci. U.S.A. 2013, 110(22):9078-9083.
64. Stevens A., Bock M., Ellis S., LeTissier P., Bishop K.N., Yap M.W., Taylor W., Stoye J.P. Retroviral capsid determinants of Fv1 NB and NR tropism. J. Virol. 2004, 78(18):9592-9598.
65. Strebel K., Klimkait T., Martin M.A. A novel gene of HIV-1, vpu, and its 16-kilodalton product. Science 1988, 241(4870):1221-1223.
66. Svarovskaia E.S., Xu H., Mbisa J.L., Barr R., Gorelick R.J., Ono A., Freed E.O., Hu W.S., Pathak V.K. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J. Biol. Chem. 2004, 279(34):35822-35828.
67. Swiecki M., Scheaffer S.M., Allaire M., Fremont D.H., Colonna M., Brett T.J. Structural and biophysical analysis of BST-2/Tetherin ectodomains reveals an evolutionary conserved design to inhibit virus release. J. Biol. Chem. 2011, 286(4):2987-2997.
68. Swiecki M., Wang Y., Gilfillan S., Lenschow D.J., Colonna M. Cutting edge: paradoxical roles of BST2/Tetherin in promoting type I IFN response and viral infection. J. Immunol. 2012, 188(6):2488-2492.
69. Takeda E., Tsuji-Kawahara S., Sakamoto M., Langlois M.-A., Neuberger M.S., Rada C., Miyazawa M. Mouse APOBEC3 restricts friend leukemia virus infection and pathogenesis in vivo. J. Virol. 2008, 82(22):10998-11008.
70. Van Damme N., Goff D., Katsura C., Jorgenson R.L., Mitchell R., Johnson M.C., Stephens E.B., Guatelli J. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 2008, 3(4):245-252.
71. Varthakavi V., Smith R.M., Bour S.P., Strebel K., Spearman P. Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production. Proc. Natl. Acad. Sci. U.S.A. 2003, 100(25):15154-15159.
72. Vasudevan A.A., Smits S.H., Hoppner A., Haussinger D., Koenig B.W., Munk C. Structural features of antiviral DNA cytidine deaminases. Biol. Chem. 2013, 394(11):1357-1370.
73. Venkatesh S., Bieniasz P.D. Mechanism of HIV-1 Virion Entrapment by Tetherin. PLoS Pathog. 2013, 9(7):e1003483.
74. Wills J.W., Craven R.C. Form, function, and use of retroviral gag proteins (editorial). AIDS 1991, 5(6):639-654.
75. Yan Y., Buckler-White A., Wollenberg K., Kozak C.A. Origin, antiviral function and evidence for positive selection of the gammaretrovirus restriction gene Fv1 in the genus Mus. Proc. Natl. Acad. Sci. U.S.A. 2009, 106(9):3259-3263.
76. Yang H., Wang J., Jia X., McNatt M.W., Zang T., Pan B., Meng W., Wang H.W., Bieniasz P.D., Xiong Y. Structural insight into the mechanisms of enveloped virus tethering by tetherin. Proc. Natl. Acad. Sci. U.S.A. 2010, 107(43):18428-18432.
77. Yang W.K., Kiggans J.O., Yang D.M., Ou C.Y., Tennant R.W., Brown A., Bassin R.H. Synthesis and circularization of N- and B-tropic retroviral DNA Fv-1 permissive and restrictive mouse cells. Proc. Natl. Acad. Sci. U.S.A. 1980, 77(5):2994-2998.
78. Yap M.W., Colbeck E., Ellis S.A., Stoye J.P. Evolution of the retroviral restriction gene Fv1: inhibition of non-MLV retroviruses. PLoS Pathog. 2014, 10(3):e1003968.
79. Yap M.W., Mortuza G.B., Taylor I.A., Stoye J.P. The design of artificial retroviral restriction factors. Virology 2007, 365(2):302-314.
80. Yu X., Yu Y., Liu B., Luo K., Kong W., Mao P., Yu X.F. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 2003, 302(5647):1056-1060.